Comparison of image georeferencing strategies for agricultural applications of small unoccupied aircraft systems

Small unoccupied aircraft systems (sUAS) are becoming popular for mapping applications in agriculture, and photogrammetry software is available for developing orthorectified imagery and three-dimensional surface models. Ground control points (GCPs), which are objects or locations with known geographic coordinates, may be required for accurate image georeferencing. However, few studies have compared global position equipment among sUAS or investigated the effects of GCP number or arrangement on georeferencing accuracy. The objectives of this study were to evaluate numbers and configurations of GCPs for georeferencing sUAS-acquired images and determine the GCP requirements for sUAS with and without real-time kinematic (RTK) global positioning equipment. The effects of varying numbers and configurations of GCPs were investigated on both a 0.40-ha area the size of a typical plant breeding trial and a 64.7-ha area (i.e., a U.S. quarter section) the size of a typical agricultural production field. Results demonstrated that four GCPs placed at the corners of the breeding-scale field resulted in two-dimensional (2D) error of ±3 cm in the absence of RTK, with minimal improvements when including more GCPs. The orthomosaics from the RTK-equipped sUAS demonstrated improved 2D accuracy even without the use of GCPs, with a maximum mean error of 0.08 m. Four GCPs were found to be sufficient to reduce altitudinal (Z) error, with maximum mean error of only 0.05 and 1.98 m for the RTK and non-RTK flights, respectively, for the production-scale field. Thus, using four GCPs, RTK-equipped sUAS, or a combination will result in improved georeferencing for photogrammetry products. © 2021 The Authors. The Plant Phenome Journal published by Wiley Periodicals LLC on behalf of American Society of Agronomy and Crop Science Society of AmericaOpen access journalThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

Variability in free 25(OH) vitamin D levels in clinical populations

Our goal was to determine total and directly measured free 25-hydroxy vitamin D (25(OH)D) serum levels in humans with a range of 25(OH)D levels and clinical conditions associated with low and high vitamin D binding protein levels. Serum samples and clinical data were collected from 106 subjects: 62 without cirrhosis or pregnancy, 24 cirrhotic patients with albumin <2.9 g/dL, and 20 pregnant women. Total 25(OH)D (LC/MS/MS) and “free” 25(OH)D (immunoassay) were measured. Total 25(OH)D was significantly lower in liver disease patients but free 25(OH)D concentrations were significantly higher in this group (p<.001). Neither total nor free 25(OH)D concentrations were significantly different in pregnant women vs. the comparator group. There were significant direct positive relationships between free 25(OH)D and total 25(OH)D concentrations for the entire dataset and for each group (p<.0001), however slopes of relationships differed in the cirrhotic group compared to pregnant women or the comparator group. In cirrhotics: y (free 25(OH)D) = 2.52 + 0.29 * X(total 25 (OH)D), r(2) = .51, p<.001; y = 1.45 +0 .09 * X; r(2) = .77, p<.0001 for pregnant women; and y = 1.11 + 0.12 * X; r(2) = .72, p<.0001 for the comparator group). Conclusions: directly measured free 25(OH)D serum concentrations and relationships between total and free 25(OH)D vary with clinical conditions, and may differ from those predicted by indirect estimation methods

Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.

Although practice guidelines recommend outpatient care for selected, haemodynamically stable patients with pulmonary embolism, most treatment is presently inpatient based. We aimed to assess non-inferiority of outpatient care compared with inpatient care

Innovative methodology in the discovery of novel drug targets in the free-living amoebae

Despite advances in drug discovery and modifications in the chemotherapeutic regimens, human infections caused by free-living amoebae (FLA) have high mortality rates (~95%). The FLA that cause fatal human cerebral infections include Naegleria fowleri, Balamuthia mandrillaris and Acanthamoeba spp. Novel drug-target discovery remains the only viable option to tackle these central nervous system (CNS) infection in order to lower the mortality rates caused by the FLA. Of these FLA, N. fowleri causes primary amoebic meningoencephalitis (PAM), while the A. castellanii and B. Mandrillaris are known to cause granulomatous amoebic encephalitis (GAE). The infections caused by the FLA have been treated with drugs like Rifampin, Fluconazole, Amphotericin-B and Miltefosine. Miltefosine is an anti-leishmanial agent and an experimental anti-cancer drug. With only rare incidences of success, these drugs have remained unsuccessful to lower the mortality rates of the cerebral infection caused by FLA. Recently, with the help of bioinformatic computational tools and the discovered genomic data of the FLA, discovery of newer drug targets has become possible. These cellular targets are proteins that are either unique to the FLA or shared between the humans and these unicellular eukaryotes. The latter group of proteins has shown to be targets of some FDA approved drugs prescribed in non-infectious diseases. This review out-lines the bioinformatic methodologies that can be used in the discovery of such novel drug-targets, their chronicle by in-vitro assays done in the past and the translational value of such target discoveries in human diseases caused by FLA